The porphyrias

Photodermatology Photoimmunology and Photomedicine

Volumn 18, Issue 2, 2002, Pages 56-67

  Sassa, Shigeru ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; BETA CAROTENE; CARBOHYDRATE; CHLOROQUINE; COPROPORPHYRINOGEN OXIDASE; FERROCHELATASE; HEMATIN; OXYGEN RADICAL; PORPHOBILINOGEN; PORPHOBILINOGEN DEAMINASE; PORPHOBILINOGEN SYNTHASE; PROTOPORPHYRINOGEN OXIDASE; SUNSCREEN; UROPORPHYRINOGEN;

ACUTE INTERMITTENT PORPHYRIA; CONGENITAL ERYTHROPOIETIC PORPHYRIA; CONTROLLED STUDY; DIETARY INTAKE; DISEASE CLASSIFICATION; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME STRUCTURE; ERYTHROPOIETIC PROTOPORPHYRIA; GASTROINTESTINAL SYMPTOM; HEPATIC PORPHYRIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PHOTOSENSITIVITY; PORPHYRIA CUTANEA TARDA; PORPHYRIA VARIEGATA; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; URINALYSIS;

DIAGNOSIS, DIFFERENTIAL; HUMANS; PORPHYRIAS; RISK FACTORS;

EID: 0036265130     PISSN: 09054383     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0781.2002.180202.x     Document Type: Review

References (96)

1. The porphyries
2. The porphyrias
3. Increase in activity of δ-aminolevulinic acid synthetase in liver mitochondria induced by feeding of 3,5-dicarbethoxy-1,4-dihydrocollidine
4. Induction of δ-aminolevulinic acid synthetase in chick embryo liver cells in culture
5. Effects by heme, insulin, and serum albumin on heme and protein synthesis in chick embryo liver cells cultured in a chemically defined medium, and a spectrofluorometric assay for porphyrin composition
6. The enzymatic catabolism of hemoglobin: Stimulation of microsomal heme oxygenase by hemin
7. Regulation of and physiological implication in heme catabolism
8. Heme biosynthesis in erythroid cells. The distinctive aspects of the regulatory mechanism
9. Molecular biology of eukaryotic 5-aminolevulinate synthase
10. The putative iron-responsive element in the human erythroid 5-aminolevulinate synthase mRNA mediates translational control
11. Loops and bulge/loops in ironresponsive element isoforms influence iron regulatory protein binding. Fine-tuning of mRNA regulation?
12. Molecular cloning of a cDNA for human δ-aminolevulinate dehydratase
13. δ-Aminolevulinic acid dehydratase assay
14. Human δ-aminolevulinate dehydratase (ALAD) gene. Structure and alternative splicing of the erythroid and housekeeping mRNAs
15. Some biochemical and clinical aspects of lead intoxication
16. Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of δ-aminolevulinic acid dehydratase activity by succinylacetone
17. On the genetic defects in hereditary tyrosinemia
18. Highly heterogenous nature of δ-aminolevulinate dehydratase (ALAD) deficiencies in ALAD porphyria
19. New type of acute porphyria with porphobilinogen synthase (d-aminolevulinic acid dehydratase) defect in the homozygous state
20. Novel molecular defects of the δ-aminolevulinate dehydratase gene in a patient with inherited acute hepatic porphyria
21. Cloning and expression of the defective genes from a patient with d-aminolevulinate dehydratase porphyria
22. δ-Aminolevulinate dehydratase deficient porphyria. Identification of the molecular lesions in a severely affected homozygote
23. Molecular analysis of δ-aminolevulinate dehydratase deficiency in a patient with an unusual late-onset porphyria
24. Genetic expression of porphobilinogen deaminase and uroporphyrinogen decarboxylase during the erythroid differentiation of mouse erythroleukemic cells
25. Alterations in haem biosynthesis during the human menstrual cycle. Studies in normal subjects and patients with latent and active acute intermittent porphyria
26. Acute intermittent porphyria. Effect of diet and griseofulvin
27. Factors affecting the excretion of porphyrin precursors by patients with acute intermittent porphyria. I. The effects of diet
28. A point mutation G A in exon 12 of the porphobilinogen deaminase gene results in exon skipping and is responsible for acute intermittent porphyria
29. Heme in the treatment of porphyrias and hematological disorders
30. Uroporphyrinogen III synthase. An alternative promoter controls erythroid-specific expression in the murine gene
31. Erythropoietic (congenital) porphyria. a rare abnormality of normoblasts
32. Congenital erythropoietic porphyria. Identification of exonic mutations in the uroporphyrinogen 111 synthase gene
33. Treatment of photosensitivity in congenital erythropoietic porphyria (CEP) with beta-carotene
34. Congenital erythrpoietic porphyria. II. The effects of induced polycythemia
35. Familial and sporadic porphyria cutanea: Two different diseases
36. Decreased activity of hepatic uroporphyrinogen decarboxylase in sporadic porphyria cutanea tarda
37. Erythrocyte uroporphyrinogen decarboxylase activity in porphyria cutanea tarda. A study of 40 consecutive patients
38. Porphyria cutanea tarda: Clinical features and laboratory findings in forty patients
39. Hepatitis C virus and porphyria cutanea tarda: Evidence of a strong association
40. Porphyria cutanea tarda associated with the acquired immune deficiency syndrome
41. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyries
42. Ascorbic acid deficiency in porphyria cutanea tarda
43. Liposoluble vitamins and naturally occurring carotenoids in porphyria cutanea tarda
44. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda
45. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America
46. Activation of the complement system in patients with porphyries after irradiation in vivo
47. Photodynamic action of uroporphyrin on the complement system in porphyria cutanea tarda
48. Activation of complement by 405-nm light in serum from porphyria cutanea tarda
49. Complement cleavage products in the phototoxic reaction of Porphyria Cutanea Tarda
50. Porphyrin-induced photodamage as related to the subcellular localization of the porphyrins
51. Porphyria cutanea tarda associated with the acquired immunodeficiency syndrome
52. Porphyria cutanea tarda and human immunodeficiency virus infection
53. Rapid procedure for fecal porphyrin assay
54. Recovery from porphyria cutanea tarda with no specific therapy other than avoidance of hepatic toxins
55. Der späten Hautporphyrie (Porphyria Cutanea Tarda) als Hinweise für deren Behandlung
56. Effect of chloroquine on hepatic uroporphyrin metabolism in patients with porphyria cutanea tarda
57. A new uroporphyrinogen decarboxylase defect or homozygous porphyria cutanea tarda?
58. Hepatoerythropoietic porphyria. clinical, biochemical, and enzymatic studies in a three-generation family lineage
59. Assignment of the gene for uroporphyrinogen decarboxylase to human chromosome I by somatic cell hybridization and specific enzyme immunoassay
60. Assignment of human uroporphyrinogen decarboxylase (URO-D) to the p34 band of chromosome 1
61. Molecular cloning and tissue-specific expression analysis of human porphobilinogen deaminase and uroporphyrinogen decarboxylase
62. Molecular cloning and nucleotide sequence of a complete human uroporphyrinogen decarboxylase cDNA
63. A mutation (G281E) of the human uroporphyrinogen decarboxylase gene causes both hepatoerythropoietic porphyria and overt familial porphyria cutanea tarda: Biochemical and genetic studies on Spanish patients
64. Uroporphyrinogen decarboxylase. complete human gene sequence and molecular study of three families with hepatoerythropoietic porphyria
65. A point mutation in the coding region of uroporphyrinogen decarboxylase associated with familial porphyria cutanea tarda
66. Uroporphyrinogen decarboxylase. a splice site mutation causes the deletion of exon 6 in multiple families with porphyria cutanea tarda
67. Five new mutations in the uroporphyrinogen decarboxylase gene identified in families with cutaneous porphyria
68. Familial porphyria cutanea tarda: Characterization of seven novel uroporphyrinogen decarboxylase mutations and frequency of common hemochromatosis alleles
69. Porphyria cutanea tarda
70. Analysis of uroporphyrinogen decarboxylase complementary DNAs in sporadic porphyria cutanea tarda
71. Uroporphyrinogen decarboxylase structural mutant (Gly281Glu) in a case of porphyria
72. Molecular analysis of uroporphyrinogen decarboxylase deficiency in a family with two cases of hepatoerythropoietic porphyria
73. Homozygous case of hereditary coproporphyria
74. Differential regulation of mouse coproporphyrinogen oxidase gene expression in erythroid and non-erythroid cells
75. Hereditary coproporphyria
76. Harderoporphyria: A variant hereditary coproporphyria
77. The clinical and biochemical features of variegate porphyria: An analysis of 300 cases studied at Groote Schuur Hospital, Cape Town
78. The porphyries. A study of inheritance and environment
79. Increased erythrocyte protoporphyrin in homozygous variegate porphyria
80. Homozygous variegate porphyria: Two similar cases in unrelated families
81. Homozygous variegate porphyria. A severe skin disease of infancy
82. Partial characterization and assignment of the gene for protoporphyrinogen oxidase and variegate porphyries to human chromosome 1q23
83. The excretion of perphyrin-peptide conjugtes in porphyria variegate
84. A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria
85. Molecular characterization of homozygous variegate porphyria
86. Homozygous variegate porphyria identification of mutations on both alleles of the protoporphyrinogen oxidase gene in a severely affected proband
87. Indentification of a new mutation responsible for hepatoerythropoietic porphyria
88. Structure of the human ferrochelatase gene: Exon/intron gene organization and location of the gene to chromosome 18
89. Porphyrins and related compounds as photodynamic sensitizers
90. Light-induced release of protoporphyrin, but not of zinc protoporphyrin, from erythrocytes in a patient with greatly elevated erythropoietic protoporphyria
91. Modulation of the phenotype in dominant erythropoietic protoporphyria by a low expression of the normal ferrochelatase allele
92. Inheritance in erythropoietic protoporphyria: A common wild-type ferrochelatase allelic variant with low expression accounts for clinical manifestation
93. Human erythropoietic protoporphyria: Two point mutations in the ferrochelatase gene
94. Systemic photoprotection
95. Zinc as an oral photoprotective agent in erythropoietic protoporphyria?